Pro-Pointer, Inc. Enters Negotiations With Two International Wholesale Pharmaceutical Distributors
February 19 2010 - 4:33PM
Marketwired
Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned
subsidiary Coenzyme-A Technologies, Inc. is pleased to announce
they are beginning distribution negotiations with ERC Saglik
Urunleri, a Mediterranean Company and also Global Pharmaceuticals,
a North African Company. Both of these companies are leading
international wholesale pharmaceutical distributors for the
medical-optical devices and pharmaceutical equipment and
nutraceutical and have a large customer base in the Mediterranean
region, North Africa and the Middle East territories. Erc Saglik
Urunleri is currently serving many of the over 1100 hospitals,
18,000 independent pharmacies and approximately 22,000 independent
medical practices in their respective territories.
ABOUT COENZYME-A TECHNOLOGIES, INC. --
Coenzyme-A Technologies, Inc. is an innovative company that
has applied new technology to the formulation and manufacture of a
series of proprietary products which address nutritional
deficiencies that result from the stress of modern day living,
chemical imbalances within the body, and the deleterious effects of
aging. Coenzyme-A is the first nutraceutical product to combine
nutritional components that can be successfully used by the body to
support its manufacture and utilization of cellular Coenzyme-A (The
Master Coenzyme). Coenzyme-A contains a specific set of substrates
that are designed to assist the body in converting fats,
carbohydrates and proteins into energy at the cellular level.
See Company website --
www.coenzyme-a.com.
FORWARD LOOKING STATEMENTS The information
contained in this news release, other than historical information,
consists of forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange
Act. These statements may involve risks and uncertainties that
could cause actual results to differ materially from those
described in such statements. Such forward-looking statements
involve known and unknown risks and uncertainties, including all
business uncertainties relating to product development, marketing,
market acceptance, future capital requirements, competition in
general and other factors that may cause actual results to be
materially different from those described herein as anticipated,
believed, estimated or expected. The Company is under no obligation
to (and expressly disclaims any such obligation to) update or alter
its forward-looking statements whether as a result of new
information, future events or otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine
INVESTOR RELATIONS at: InvestSource, Inc. 6352 Santa Ynez Dr.
Huntington Beach, CA 92647 Phone (714) 847-2460 Fax (714)
847-4987
Coenzyme A (CE) (USOTC:PPII)
Historical Stock Chart
From Nov 2024 to Dec 2024
Coenzyme A (CE) (USOTC:PPII)
Historical Stock Chart
From Dec 2023 to Dec 2024